MedTrace Logo

Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell

NCT02916316 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 127

Last updated 2025-11-18

No results posted yet for this study

Summary

All patients enrolled in the study will have to be treated with a chemo immunotherapy scheme R-CHOP with doxorubicin, with doxorubicin analogue or non pegylated liposomal anthracycline (R-COMP; Sec. 648 DM) administered every 21 days for 6 cycles. In unfavourable patients (stage II-IV) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of R-CHOP.

Conditions

  • Lymphoma
  • Large B-Cell
  • Diffuse Large B-Cell

Interventions

DRUG

R-CHOP with doxorubicin

Chemoimmunotherapy every 21 days for 6 cycles. In unfavourable patients (stage II-IV) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of R-CHOP.

Sponsors & Collaborators

  • Fondazione Italiana Linfomi - ETS

    lead OTHER

Principal Investigators

  • Guido Gini, MD · AOU Ospedali Riuniti, Ematologia ANCONA

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-12
Primary Completion
2020-12-30
Completion
2024-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02916316 on ClinicalTrials.gov